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Conclusions: Even	 low	 doses	 of	 corticosteroids	 frequently	 lead	 to	 substantial	 ad‐
verse	events	refuting	the	assumption	that	adverse	events	are	prevented	by	adminis‐
tering	low	doses.
2  |     van den BRand et al.
1  | INTRODUC TION
Autoimmune	 hepatitis	 is	 a	 severe	 immune‐mediated	 inflammation	
of	unknown	aetiology	that	primarily	targets	hepatocytes.	Treatment	
is	 aimed	 to	prevent	disease	 relapse,	 relieve	 symptoms	and	achieve	
full	 biochemical	 and	 histological	 normalisation	 in	 order	 to	 prevent	
progression	to	fibrosis,	cirrhosis	and	end‐stage	liver	failure	requiring	




















In	 this	 study,	 we	 focused	 on	 three	 frequently	 occurring	 and	
documented	adverse	events.	We	aimed	to	assess	 the	 incidence	of	
cataract,	diabetes	and	osteoporotic	fractures	in	relation	to	cortico‐
steroid	 doses	 in	 the	 long‐term	maintenance	 treatment	 of	 patients	
with	autoimmune	hepatitis.8













The	 clinical	 characteristics	 including	 adverse	 events	 and	











and	 surgery	 reports	 and	 imaging	 reports.	 Normal	 bone	 density,	 
osteopenia	and	osteoporosis	were	defined	as	T‐scores	above	−1.0;	 
−1	 to	 −2.5	 and	 −2.5	 or	 lower	 respectively.	 Autoimmune	 hepatitis	











hepatitis	 were	 discarded.	 In	 the	 case	 of	multiple	 fractures	 in	 one	
patient,	only	 the	date	of	 the	 first	 fracture	was	used	 in	 the	model.	
Factors	 that	 were	 possibly	 predictive	 of	 adverse	 events	 and	 that	
were	available	 in	 the	database,	were	 included	simultaneous	 in	 the	
multivariate	model	to	provide	estimates	adjusted	for	other	factors/
predictors.	 The	 doses	 of	 immunosuppressive	 therapy	 and	 the	 oc‐
currence	of	adverse	events	were	analysed	per	patient	per	follow‐up	
year.	For	every	year,	a	patient	was	at	risk	of	developing	an	adverse	
event,	 the	age	 in	 that	year	was	used.	By	 these	means,	ageing	was	
taken	into	account.	In	addition,	the	effect	of	the	predniso(lo)ne	dose	
in	 the	 prior	 years	was	 assessed.	 Patient‐years	without	 the	 use	 of	
predniso(lo)ne	 or	 budesonide	 were	 used	 as	 reference	 categories.	
The	outcome	 is	 described	as	 an	estimation	of	 the	odds	 ratio	with	
its	95%	CI.	The	 level	of	 significance	 (α)	was	set	at	0.05.	Statistical	
analyses	were	performed	with	IBM	SPSS	22.0.
3  | RESULTS
A	 total	 of	 476	 patients	with	 a	median	 follow‐up	 time	 of	 13	 years	








were	 predniso(lo)ne	 and	 azathioprine.	 In	 total,	 428	 (90%)	 patients	
were	prescribed	predniso(lo)ne.	Of	the	years	that	predniso(lo)ne	was	
     |  3van den BRand et al.
used	 in	these	patients,	 the	mean	daily	dose	was	≤	5.0	mg	 (n	=	96;	
20%),	5.1‐10	mg	(n	=	272;	56%)	or	>	10	mg	(n	=	67;	14%).	Budesonide	
was	prescribed	to	84	(17%)	patients	in	mean	daily	doses	of	0.1‐3	mg	






In	120	 (25%)	patients	 cataract,	 diabetes	or	one	or	more	 fractures	
occurred	after	the	diagnosis	of	autoimmune	hepatitis.	The	effect	of	
one	additional	daily	milligram	predniso(lo)ne	or	budesonide	on	the	

















increase	 the	 odds	 of	 cataract	 (Figure	 1,	 panel	 B).	 Budesonide	 use	
 Autoimmune hepatitis AIH‐PBC AIH‐PSC
Patients,	n	(%) 406	(87) 30	(6) 40	(9)















ANA	positive,	n	(%) 268	(74) 13	(43) 23	(70)





TA B L E  1  Characteristics	at	diagnosis
TA B L E  2  Treatment	details	of	patients	with	autoimmune	hepatitis
 




Years of use, median 
(range)
Dose mg/d median 
(range)
Predniso(lo)ne 3767	(57) 429	(90) 7	(1‐39) 8	(1.67‐33.75)
Budesonide 449	(7) 85	(18) 4	(1‐16) 6	(1‐12)
Azathioprine 4541	(68) 392	(82) 12	(1‐34) 73	(4‐500)
Mycophenolate	mofetil 195	(3) 33	(7) 6	(1‐15) 1000	(50‐4000)
Ciclosporin 66	(1) 11	(2) 6	(1‐14) 138	(13‐400)
Tacrolimus 28	(0) 6	(1) 5	(1‐8) 5	(0.7‐12.0)
Mercaptopurine 60	(1) 15	(3) 2	(1‐21) 50	(1‐100)
Tioguanine 35	(1) 9	(2) 2	(1‐10) 18	(3‐50)
Allopurinol 39	(1) 14	(3) 3	(1‐6) 100	(50‐100)
Ursodeoxycholic	acid 1661	(25) 164	(34) 11	(1‐28) 825	(50‐1800)
aThe	total	patient‐years	was	6634.	








age	 in	 that	 year.	 The	 predniso(lo)ne	 and	 budesonide‐associated	
increase	 in	 odds	 ratio	 persisted	 after	 correction	 for	 predniso(lo)
ne	 use	 in	 the	 prior	 year	 before	 the	 fracture	 (Figure	 1,	 panel	D).	







cess	 fractures	 (n	 =	 1;	 1%).	Osteoporotic	 vertebral	 fractures	 can	
occur	asymptomatic	and	slowly	over	time,	subsequently	the	date	
of	 diagnosis	 on	X‐ray	 can	be	different	 from	 the	onset.	Hence,	 a	
sub	analysis	 including	fractures	with	a	preceding	trauma	and	ex‐
cluding	 vertebral	 fractures	was	 performed.	 This	 analysis	 further	
characterised	the	effect	of	predniso(lo)ne	(0.1‐5.0	mg/d),	but	not	
of	budesonide	(Figure	S1)	on	nonvertebral	fractures.	Predniso(lo)





P valueOdds ratio (95% CI) Odds ratio (95% CI)
Combined	primary	adverse	
events
1.08 1.06‐1.11 <.001 1.09 1.00‐1.20 .06
Primary	adverse	event
Cataract 1.06 1.03‐1.10 <.001 1.17 1.02‐1.33 .02
Diabetes 1.09 1.05‐1.12 <.001 0.96 0.70‐1.30 .78
Bone	fracture 1.05 1.01‐1.10 .01 1.14 1.03‐1.27 .02
Note: Generalised	estimated	equations,	corrected	for	sex	and	age	at	that	year.
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showed	 a	 normal	 bone	 density	 (37%;	 n	 =	 96),	 osteopenia	 (49%;	
n	=	128)	or	osteoporosis	 (14%;	n	=	37).	 In	13	hospitals	 (n	=	369	
patients),	data	on	treatment	to	prevent	bone	loss	were	available.	
Medication	 to	prevent	or	 treat	bone	 loss	was	prescribed	 to	265	
(72%)	patients	and	consisted	of	calcium	carbonate	(n	=	247;	67%),	
vitamin	D	(n	=	210;	57%),	bisphosphonate	(n	=	165;	45%)	and	de‐














a	 significant	 predictor	 (P	 =	 .05,	 Figure	 1F).	 The	 effect	 of	 pred‐
niso(lo)ne	on	 the	odds	of	diabetes	persisted	 for	1	year	 (P	=	 .05),	
whereas	predniso(lo)ne	doses	2	years	 (P	=	 .3)	or	3	years	 (P	=	 .1)	










3.2 | Patients with autoimmune hepatitis 
variant syndromes
The	odds	of	cataract,	diabetes	and	fractures	was	similar	when	pa‐
tients	 with	 an	 autoimmune	 hepatitis	 variant	 with	 primary	 biliary	




nificant	 differences	were	 observed	 in	 predniso(lo)ne,	 budesonide,	




The	 results	 of	 this	 study	 re‐establish	 the	 fracture	 risk	 in	 patients	
taking	corticosteroids.	Here	we	show	that	in	patients	with	autoim‐







occurrence	 of	 adverse	 events	 increases	with	 increasing	 doses	 in	
our	 and	other	 studies.14‐16	 In	our	 cohort,	 the	odds	of	 new‐onset	
fractures	increased	even	when	low	average	doses	of	≤5	mg	pred‐
niso(lo)ne	was	prescribed,	whereas	the	odds	of	diabetes	and	cat‐





events.	 Vertebral	 compression	 fractures	 are	 the	 most	 common	
type	of	low‐trauma	osteoporotic	fractures	and	were	the	most	fre‐
quent	observed	fractures	in	our	cohort.	This	is	in	line	with	a	large	
study	 from	 the	 United	 Kingdom	 that	 found	 an	 increased	 risk	 of	







odds	 of	 fractures	 and	 cataract.	 This	 effect	 persisted	 after	 correc‐
tion	for	predniso(lo)ne	use	 in	the	years	prior	 to	these	events,	sug‐
gesting	 that	 the	 ‘topically’	 acting	budesonide	does	not	completely	
prevent	an	increase	in	the	odds	of	fractures	or	cataract	and	may	be	








autoimmune	 hepatitis	 treated	 with	 budesonide	 after	 prior	 occur‐
rence	of	prominent	side	effects	on	prednisone.	In	addition,	Manns	
et al19	found	significantly	less	short‐term	corticosteroid‐specific	side	
effects	 in	 autoimmune	hepatitis	 patients	 treated	with	 budesonide	
compared	 to	 predniso(lo)ne.	 This	 is	 supported	 by	 evidence	 in	 the	
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rheumatoid	 arthritis,16	 systemic	 lupus	erythematosus,21	 inflammatory	






autoimmune	 hepatitis,	 both	 doses	 and	 corticosteroid‐related	 adverse	
events	decreased.25‐27	However,	recently	the	International	Autoimmune	
Hepatitis	Study	Group	emphasised	that	concerns	regarding	corticoste‐































available.	 Finally,	 the	 types	of	 cataracts	were	 not	 distinguished	 in	
our	 cohort	 and	we	 lumped	 the	 total	 number	of	 cataracts	 that	oc‐
curred	and	could	not	assess	the	proportion	of	corticosteroid‐related	
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